Nutrition and metabolic insights · 2025
Sarcopenic Obesity in Adult Patients: Prevalence and Risk Factors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khamassi Sana, Boukhayatia Fatma, Abdesselem Haifa, Bornaz Emna, Ounaissa Kamilia, Bouhajja Houda, Kacem Awatef, Gammoudi Amel, Mahjoub Rahma, Talbi Emna, Jamoussi Henda, Amrouche Chiraz
Аннотация
BACKGROUND: Sarcopenia now constitutes a serious issue that can affect the obese adult population. The aims of our study were to estimate the prevalence of sarcopenia in a group of obese patients, investigate the impact of sarcopenic obesity (SO) on patient health and quality of life, and identify its risk factors.
METHODS: We conducted a cross-sectional descriptive observational study of a group of obese adult patients. Physical activity was assessed with the Ricci and Gagnon questionnaire and quality of life was evaluated using the SF-12 and ORWELL-97 questionnaires. SO was defined in accordance with the EASO-ESPEN consensus statement.
RESULTS: We included 100 patients with a mean age of 44.42 ± 13.25 years. SO was diagnosed in 19% of the study population. The assessment of the impact of SO revealed that it was associated with osteoarthritis (P < .0001), functional disability (P = .001) and obesity-specific quality of life impairment (P < .0001). SO was associated with lower education levels (P = .011), a low score in the daily physical activities' dimension of the Ricci and Gagnon score (P = .028), class 2 obesity (P = .032), elevated blood triglyceride levels (P = .019), potassium and manganese intake deficiency (P = .042 and P = .004, respectively). Non-sarcopenic obese patients had a higher frequency of a history of weight loss interventions (P = .038), excess protein intake (P = .042), and excess lipid intake (P = .011). Multivariate analysis identified class 2 obesity (P = .048), osteoarthritis (P = .038), elevated triglyceride levels (P = .049), manganese deficiency intake (P = .026), increased score in the daily physical activities' dimension (P = .048), increased gait speed (P = .025) and excess fat intake (P = .047) as factors independently associated with SO.
CONCLUSION: It is essential to incorporate the screening for sarcopenia into the therapeutic approach for obese adult patients due to its clinical consequences and impact on individuals' quality of life.
METHODS: We conducted a cross-sectional descriptive observational study of a group of obese adult patients. Physical activity was assessed with the Ricci and Gagnon questionnaire and quality of life was evaluated using the SF-12 and ORWELL-97 questionnaires. SO was defined in accordance with the EASO-ESPEN consensus statement.
RESULTS: We included 100 patients with a mean age of 44.42 ± 13.25 years. SO was diagnosed in 19% of the study population. The assessment of the impact of SO revealed that it was associated with osteoarthritis (P < .0001), functional disability (P = .001) and obesity-specific quality of life impairment (P < .0001). SO was associated with lower education levels (P = .011), a low score in the daily physical activities' dimension of the Ricci and Gagnon score (P = .028), class 2 obesity (P = .032), elevated blood triglyceride levels (P = .019), potassium and manganese intake deficiency (P = .042 and P = .004, respectively). Non-sarcopenic obese patients had a higher frequency of a history of weight loss interventions (P = .038), excess protein intake (P = .042), and excess lipid intake (P = .011). Multivariate analysis identified class 2 obesity (P = .048), osteoarthritis (P = .038), elevated triglyceride levels (P = .049), manganese deficiency intake (P = .026), increased score in the daily physical activities' dimension (P = .048), increased gait speed (P = .025) and excess fat intake (P = .047) as factors independently associated with SO.
CONCLUSION: It is essential to incorporate the screening for sarcopenia into the therapeutic approach for obese adult patients due to its clinical consequences and impact on individuals' quality of life.